Skip to content

Multicenter randomized parallel controlled clinical study of cephalic acupuncture point series long duration of needle retention therapy for mild cognitive impairment (MCI) after stroke: a randomized controlled trial

Multicenter randomized parallel controlled clinical study of cephalic acupuncture point series long duration of needle retention therapy for mild cognitive impairment (MCI) after stroke: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069236
Enrollment
Unknown
Registered
2023-03-10
Start date
2023-03-10
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment after stroke

Interventions

Control group:Basic therapy + cognitive function training
Common head needle group:Basic therapy + cognitive function training + head needle therapy (no needle left)
Cephalic point acupunctur long duration of needle retention group:Basic therapy + cognitive function training + cephalic point acupunctur long duration of needle retention

Sponsors

He'nan Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of He'nan University of Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for cerebral infarction/cerebral hemorrhage; 2. Meet the diagnostic criteria for mild cognitive impairment after stroke: there is impairment in at least one cognitive domain, but the diagnostic criteria for dementia are not met. Simple Intelligent Mental State Scale (MMSE) : illiterate (uneducated) >=17 points, primary school (years of education =20 points, above secondary school (years of education >6 years) >=24 points; Montreal Cognitive Assessment Scale (MoCA) < 26; 3. Aged between 18 and 75 years; 4. Cognitive dysfunction within 6 months after stroke; 5. Memory impairment (private complaint, provided by others); 6. Instrumental daily living ability may be normal or mildly impaired, but should be independent of motor/sensory symptoms; 7. The patient was conscious and his vital signs were stable; 8. Education level above primary school; 9. Did not participate in clinical studies of other interventions within 1 month before inclusion; 10. The study was reviewed and approved by the hospital ethics committee in accordance with the Declaration of Helsinki and Measures for Ethical Review of Biomedical Research Involving Humans (Trial). The patient gave full informed consent and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with serious diseases such as heart, liver, kidney or malignant tumor who cannot cooperate; 2. Patients with obvious hearing, vision, aphasia, cognitive dysfunction and other physical examination evaluation can not cooperate; 3. Mild cognitive impairment prior to stroke; 4. Other physical and mental disorders leading to dementia and brain dysfunction; 5. Patients who are pregnant or have the intention of becoming pregnant and breastfeeding patients.

Design outcomes

Primary

MeasureTime frame
Montreal cognitive assessment scale;

Secondary

MeasureTime frame
Simple intelligent mental state scale;Cognitive function event-related potential P300 (ERP-P300);

Countries

China

Contacts

Public ContactKong Yanfang

He'nan Provincial Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of He'nan University of Chinese Medicine)

382196079@qq.com+86 187 3713 7181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026